Endocrine disruptors: New players in the pathophysiology of type 2 diabetes?

Diabetes and Metabolism

Volumn 41, Issue 2, 2015, Pages 107-115

  Chevalier, N ^a,b,c   Fenichel P ^a,b,c  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b INSERM   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Bisphenol A; Diabetes; Endocrine disruptors; Oestrogens; Pollutants; Type 2 diabetes

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ENDOCRINE DISRUPTOR; ESTROGEN DERIVATIVE; PHTHALIC ACID DERIVATIVE; POLLUTANT;

ANIMAL EXPERIMENT; CELL FUNCTION; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGICAL DATA; GLUCOSE HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PERSISTENT ORGANIC POLLUTANT; REVIEW; ADVERSE EFFECTS; CHEMICALLY INDUCED; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PHYSIOLOGY; POLLUTANT;

DIABETES MELLITUS, TYPE 2; ENDOCRINE DISRUPTORS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X;

EID: 84926681665     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2014.09.005     Document Type: Review

References (83)

1. World Health Organization Diabetes (Fact Sheet N°312) 2013, http://www.who.int/mediacentre/factsheets/fs312/en/.
2. Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378:31-40.
3. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
4. International Diabetes Federation IDF Diabetes Atlas 2013, International Diabetes Federation, Brussels, Belgium. http://www.idf.org/diabetesatlas, 6th edn.
5. American Diabetes Association Economic costs of diabetes in the US in 2012. Diabetes Care 2013, 36:1033-1046.
6. Rapport de l'Assurance Maladie sur les Charges et Produits pour l'année 2014 http://www.ameli.fr/rapport-charges-et-produits-2014/appli.html.
7. Thayer K.A., Heindel J.J., Bucher J.R., Gallo M.A. Role of environmental chemicals in diabetes and obesity: a National Toxicology Program workshop review. Environ Health Perspect 2012, 120:779-789.
8. Neel B.A., Sargis R.M. The paradox of progress: environmental disruption of metabolism and the diabetes epidemic. Diabetes 2011, 60:1838-1848.
9. International Programme for Chemical Safety (IPCS) Global assessment of the state-of-the-science of endocrine disruptors Chapter 1: Executive summary 2010, 1-3.
10. Diamanti-Kandarakis E., Bourguignon J.P., Giudice L.C., Hauser R., Prins G.S., Soto A.M., et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocrine Rev 2009, 30:293-342.
11. Rousselle C., Ormsby J.N., Schaefer B., Lampen A., Platzek T., Hirsch-Ernst K., et al. Meeting report: international workshop on endocrine disruptors: exposure and potential impact on consumers health. Reg Toxicol Pharmacol 2013, 65:7-11.
12. Casals-Casas C., Desvergne B. Endocrine disruptors: from endocrine to metabolic disruption. Ann Rev Physiol 2011, 73:135-162.
13. Colborn T., vom Saal F.S., Soto A.M. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 1993, 101:378-384.
14. Mauvais-Jarvis F., Clegg D.J., Hevener A.L. The role of estrogens in control of energy balance and glucose homeostasis. Endocrine Rev 2013, 34:309-338.
15. Newbold R.R., Padilla-Banks E., Jefferson W.N. Adverse effects of the model environmental estrogen diethylstilbestrol are transmitted to subsequent generations. Endocrinology 2006, 147:S11-S17.
16. Newbold R.R., Padilla-Banks E., Jefferson W.N. Environmental estrogens and obesity. Mol Cell Endocrinol 2009, 304:84-89.
17. Barker D.J. The developmental origins of adult disease. Eur J Epidemiol 2003, 18:733-736.
18. Tiano J.P., Mauvais-Jarvis F. Importance of oestrogen receptors to preserve functional beta-cell mass in diabetes. Nat Rev Endocrinol 2012, 8:342-351.
19. Wynn V., Doar J.W. Some effects of oral contraceptives on carbohydrate metabolism. Lancet 1966, 2:715-719.
20. Andersson B., Mattsson L.A., Hahn L., Marin P., Lapidus L., Holm G., et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997, 82:638-643.
21. Brussaard H.E., Gevers Leuven J.A., Frolich M., Kluft C., Krans H.M. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997, 40:843-849.
22. Crespo C.J., Smit E., Snelling A., Sempos C.T., Andersen R.E., Nhanes Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2002, 25:1675-1680.
23. Nadal A., Rovira J.M., Laribi O., Leon-quinto T., Andreu E., Ripoll C., et al. Rapid insulinotropic effect of 17beta-estradiol via a plasma membrane receptor. Faseb J 1998, 12:1341-1348.
24. Wong W.P., Tiano J.P., Liu S., Hewitt S.C., Le May C., Dalle S., et al. Extranuclear estrogen receptor-alpha stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. Proc Natl Acad Sci U S A 2010, 107:13057-13062.
25. Soriano S., Ropero A.B., Alonso-Magdalena P., Ripoll C., Quesada I., Gassner B., et al. Rapid regulation of K(ATP) channel activity by 17{beta}-estradiol in pancreatic {beta}-cells involves the estrogen receptor {beta} and the atrial natriuretic peptide receptor. Mol Endocrinol 2009, 23:1973-1982.
26. Sharma G., Prossnitz E.R. Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic beta-cells. Endocrinology 2011, 152:3030-3039.
27. Liu S., Mauvais-Jarvis F. Rapid, nongenomic estrogen actions protect pancreatic islet survival. Islets 2009, 1:273-275.
28. Kang L., Zhang X., Xie Y., Tu Y., Wang D., Liu Z., et al. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 2010, 24:709-721.
29. Contreras J.L., Smyth C.A., Bilbao G., Young C.J., Thompson J.A., Eckhoff D.E. 17beta-Estradiol protects isolated human pancreatic islets against proinflammatory cytokine-induced cell death: molecular mechanisms and islet functionality. Transplantation 2002, 74:1252-1259.
30. Baquie M., St-Onge L., Kerr-Conte J., Cobo-Vuilleumier N., Lorenzo P.I., Jimenez Moreno C.M., et al. The liver receptor homolog-1 (LRH-1) is expressed in human islets and protects {beta}-cells against stress-induced apoptosis. Hum Mol Genet 2011, 20:2823-2833.
31. Yamabe N., Kang K.S., Zhu B.T. Beneficial effect of 17beta-estradiol on hyperglycemia and islet beta-cell functions in a streptozotocin-induced diabetic rat model. Toxicol Appl Pharmacol 2010, 249:76-85.
32. Tiano J.P., Delghingaro-Augusto V., Le May C., Liu S., Kaw M.K., Khuder S.S., et al. Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents beta cell failure in rodent models of type 2 diabetes. J Clin Invest 2011, 121:3331-3342.
33. Defronzo R.A., Banting, Lecture From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
34. Foryst-Ludwig A., Clemenz M., Hohmann S., Hartge M., Sprang C., Frost N., et al. Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma. PLoS Genet 2008, 4:e1000108.
35. Wiik A., Gustafsson T., Esbjornsson M., Johansson O., Ekman M., Sundberg C.J., et al. Expression of oestrogen receptor alpha and beta is higher in skeletal muscle of highly endurance-trained than of moderately active men. Acta Physiol Scand 2005, 184:105-112.
36. Ribas V., Nguyen M.T., Henstridge D.C., Nguyen A.K., Beaven S.W., Watt M.J., et al. Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERalpha-deficient mice. Am J Physiol Endocrinol Metab 2010, 298:E304-E319.
37. Bryzgalova G., Gao H., Ahren B., Zierath J.R., Galuska D., Steiler T.L., et al. Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver. Diabetologia 2006, 49:588-597.
38. Barros R.P., Gustafsson J.A. Estrogen receptors and the metabolic network. Cell Metab 2011, 14:289-299.
39. van Rooij E., Fielitz J., Sutherland L.B., Thijssen V.L., Crijns H.J., Dimaio M.J., et al. Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor. Circ Res 2010, 106:155-165.
40. Gong H., Xie J., Zhang N., Yao L., Zhang Y. MEF2A binding to the Glut4 promoter occurs via an AMPKalpha2-dependent mechanism. Med Scie Sports Exercise 2011, 43:1441-1450.
41. Yepuru M., Eswaraka J., Kearbey J.D., Barrett C.M., Raghow S., Veverka K.A., et al. Estrogen receptor-{beta}-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice. J Biol Chem 2010, 285:31292-31303.
42. Ruzzin J., Petersen R., Meugnier E., Madsen L., Lock E.J., Lillefosse H., et al. Persistent organic pollutant exposure leads to insulin resistance syndrome. Environ Health Perspect 2010, 118:465-471.
43. Hurst C.H., Waxman D.J. Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol Sci 2003, 74:297-308.
44. Alonso-Magdalena P., Quesada I., Nadal A. Endocrine disruptors in the etiology of type 2 diabetes mellitus. Nat Rev Endocrinol 2011, 7:346-353.
45. Novelli M., Piaggi S., De Tata V. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced impairment of glucose-stimulated insulin secretion in isolated rat pancreatic islets. Toxicol Lett 2005, 156:307-314.
46. Rubin B.S. Bisphenol A: an endocrine disruptor with widespread exposure and multiple effects. J Steroid Biochem Mol Biol 2011, 127:27-34.
47. Vandenberg L.N., Maffini M.V., Sonnenschein C., Rubin B.S., Soto A.M. Bisphenol A and the great divide: a review of controversies in the field of endocrine disruption. Endocrine Rev 2009, 30:75-95.
48. Calafat A.M., Ye X., Wong L.Y., Reidy J.A., Needham L.L. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect 2008, 116:39-44.
49. Vandenberg L.N., Hauser R., Marcus M., Olea N., Welshons W.V. Human exposure to bisphenol A (BPA). Rep Toxicol 2007, 24:139-177.
50. Nadal A., Ropero A.B., Laribi O., Maillet M., Fuentes E., Soria B. Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor alpha and estrogen receptor beta. Proc Natl Acad Sci U S A 2000, 97:11603-11608.
51. Alonso-Magdalena P., Morimoto S., Ripoll C., Fuentes E., Nadal A. The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance. Environ Health Perspect 2006, 114:106-112.
52. Alonso-Magdalena P., Ropero A.B., Carrera M.P., Cederroth C.R., Baquie M., Gauthier B.R., et al. Pancreatic insulin content regulation by the estrogen receptor ER alpha. PloS One 2008, 3:e2069.
53. Ropero A.B., Alonso-Magdalena P., Garcia-Garcia E., Ripoll C., Fuentes E., Nadal A. Bisphenol-A disruption of the endocrine pancreas and blood glucose homeostasis. Int J Androl 2008, 31:194-200.
54. Nadal A., Alonso-Magdalena P., Soriano S., Ripoll C., Fuentes E., Quesada I., et al. Role of estrogen receptors alpha, beta and GPER1/GPR30 in pancreatic beta-cells. Frontiers Biosci 2011, 16:251-260.
55. Soriano S., Alonso-Magdalena P., Garcia-Arevalo M., Novials A., Muhammed S.J., Salehi A., et al. Rapid insulinotropic action of low doses of bisphenol-A on mouse and human islets of Langerhans: role of estrogen receptor beta. PloS One 2012, 7:e31109.
56. Tohme M., Prud'homme S.M., Boulahtouf A., Samarut E., Brunet F., Bernard L., et al. Estrogen-related receptor gamma is an in vivo receptor of bisphenol A. Faseb J 2014, 28:3124-3133.
57. Kidani T., Kamei S., Miyawaki J., Aizawa J., Sakayama K., Masuno H., et al. downregulates Akt signaling and inhibits adiponectin production and secretion in 3T3-L1 adipocytes. J Atherosclerosis Thrombosis 2010, 17:834-843.
58. Masuno H., Iwanami J., Kidani T., Sakayama K., Honda K. Bisphenol a accelerates terminal differentiation of 3T3-L1 cells into adipocytes through the phosphatidylinositol 3-kinase pathway. Toxicol Sci 2005, 84:319-327.
59. Batista T.M., Alonso-Magdalena P., Vieira E., Amaral M.E., Cederroth C.R., Nef S., et al. Short-term treatment with bisphenol-A leads to metabolic abnormalities in adult male mice. PloS One 2012, 7:e33814.
60. Jimenez-Chillaron J.C., Isganaitis E., Charalambous M., Gesta S., Pentinat-Pelegrin T., Faucette R.R., et al. Intergenerational transmission of glucose intolerance and obesity by in utero undernutrition in mice. Diabetes 2009, 58:460-468.
61. Rubin B.S., Murray M.K., Damassa D.A., King J.C., Soto A.M. Perinatal exposure to low doses of bisphenol A affects body weight, patterns of estrous cyclicity, and plasma LH levels. Environ Health Perspect 2001, 109:675-680.
62. Garcia-Arevalo M., Alonso-Magdalena P., Rebelo Dos Santos J., Quesada I., Carneiro E.M., Nadal A. Exposure to bisphenol-A during pregnancy partially mimics the effects of a high-fat diet altering glucose homeostasis and gene expression in adult male mice. PloS one 2014, 9:e100214.
63. Dolinoy D.C., Jirtle R.L. Environmental epigenomics in human health and disease. Environ Mol Mutagenesis 2008, 49:4-8.
64. Skinner M.K., Manikkam M., Guerrero-Bosagna C. Epigenetic transgenerational actions of endocrine disruptors. Rep Toxicol 2011, 31:337-343.
65. Dolinoy D.C., Huang D., Jirtle R.L. Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc Natl Acad Sci U S America 2007, 104:13056-13061.
66. Singh S., Li S.S. Epigenetic effects of environmental chemicals bisphenol a and phthalates. Int J Mol Sci 2012, 13:10143-10153.
67. Manikkam M., Tracey R., Guerrero-Bosagna C., Skinner M.K. Plastics derived endocrine disruptors (BPA, DEHP and DBP) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. PloS One 2013, 8:e55387.
68. Kalfa N., Paris F., Soyer-Gobillard M.O., Daures J.P., Sultan C. Prevalence of hypospadias in grandsons of women exposed to diethylstilbestrol during pregnancy: a multigenerational national cohort study. Fertil Steril 2011, 95:2574-2577.
69. Bertazzi P.A., Consonni D., Bachetti S., Rubagotti M., Baccarelli A., Zocchetti C., et al. Health effects of dioxin exposure: a 20-year mortality study. Am J Epidemiol 2001, 153:1031-1044.
70. Michalek J.E., Pavuk M. Diabetes and cancer in veterans of Operation Ranch Hand after adjustment for calendar period, days of spraying, and time spent in Southeast Asia. J Occup Environ Med 2008, 50:330-340.
71. Wang S.L., Tsai P.C., Yang C.Y., Guo Y.L. Increased risk of diabetes and polychlorinated biphenyls and dioxins: a 24-year follow-up study of the Yucheng cohort. Diabetes Care 2008, 31:1574-1579.
72. Turyk M., Anderson H., Knobeloch L., Imm P., Persky V. Organochlorine exposure and incidence of diabetes in a cohort of Great Lakes sport fish consumers. Environ Health Perspect 2009, 117:1076-1082.
73. Magliano D.J., Loh V.H., Harding J.L., Botton J., Shaw J.E. Persistent organic pollutants and diabetes: a review of the epidemiological evidence. Diabet Metab 2014, 40:1-14.
74. Lee D.H., Lee I.K., Song K., Steffes M., Toscano W., Baker B.A., et al. A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care 2006, 29:1638-1644.
75. Everett C.J., Frithsen I.L., Diaz V.A., Koopman R.J., Simpson W.M., Mainous AG3rd Association of a polychlorinated dibenzo-p-dioxin, a polychlorinated biphenyl, and DDT with diabetes in the 1999-2002 National Health and Nutrition Examination Survey. Environ Res 2007, 103:413-418.
76. Lakind J.S., Goodman M., Mattison D.R. Bisphenol A and indicators of obesity, glucose metabolism/type 2 diabetes and cardiovascular disease: a systematic review of epidemiologic research. Crit Rev Toxicol 2014, 44:121-150.
77. Goodman M., Lakind J.S., Mattison D.R. Do phthalates act as obesogens in humans? A systematic review of the epidemiological literature. Crit Rev Toxicol 2014, 44:151-175.
78. Hong Y.C., Park E.Y., Park M.S., Ko J.A., Oh S.Y., Kim H., et al. Community level exposure to chemicals and oxidative stress in adult population. Toxicol Lett 2009, 184:139-144.
79. Ning G., Bi Y., Wang T., Xu M., Xu Y., Huang Y., et al. Relationship of urinary bisphenol A concentration to risk for prevalent type 2 diabetes in Chinese adults: a cross-sectional analysis. Ann Intern Med 2011, 155:368-374.
80. Wang T., Li M., Chen B., Xu M., Xu Y., Huang Y., et al. Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance. J Clin Endocrinol Metab 2012, 97:E223-E227.
81. Sun Q., Cornelis M.C., Townsend M.K., Tobias D.K., Eliassen A.H., Franke A.A., et al. Association of urinary concentrations of bisphenol A and phthalate metabolites with risk of type 2 diabetes: a prospective investigation in the Nurses' Health Study (NHS) and NHSII cohorts. Environ Health Perspect 2014, 122:616-623.
82. Airaksinen R., Rantakokko P., Eriksson J.G., Blomstedt P., Kajantie E., Kiviranta H. Association between type 2 diabetes and exposure to persistent organic pollutants. Diabetes Care 2011, 34:1972-1979.
83. Vandenberg L.N., Colborn T., Hayes T.B., Heindel J.J., Jacobs D.R., Lee D.H., et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocrine Rev 2012, 33:378-455.